MARKET

CERS

CERS

Cerus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.43
+0.46
+9.26%
After Hours: 5.45 +0.02 +0.37% 17:05 05/27 EDT
OPEN
5.04
PREV CLOSE
4.970
HIGH
5.54
LOW
5.00
VOLUME
2.89M
TURNOVER
0
52 WEEK HIGH
8.06
52 WEEK LOW
4.380
MARKET CAP
960.56M
P/E (TTM)
-19.0459
1D
5D
1M
3M
1Y
5Y
Class Of 1997: 25 Years Decades After Their IPOs, Where Are These Companies Now?
Delivering on a promise is a tough proposition, and to consistently deliver requires excellence on all fronts.
Benzinga · 05/19 21:00
As the Red Cross moves to a pricey blood treatment method, hospitals call for more choice
The nation’s largest supplier of platelets is moving to a method it says is easier for hospitals and reduces pathogens—but the cost is too much for hospitals who demand more options for patients.
Fortune · 05/17 09:00
Does Cerus (CERS) Have the Potential to Rally 89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cerus (CERS) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Zacks · 05/16 13:55
Cerus (NASDAQ:CERS) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 05/15 12:42
BRIEF-Cerus Corp Announces First Quarter 2022 Financial Results
reuters.com · 05/05 21:48
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:15
Cerus GAAP EPS of -$0.07 beats by $0.01, revenue of $43.02M beats by $5.53M
Cerus press release (NASDAQ:CERS): Q1 GAAP EPS of -$0.07 beats by $0.01. Revenue of $43.02M (+45.5% Y/Y) beats by $5.53M. Increasing Full-Year 2022 Product Revenue Guidance Range from $157-164 Million to $160-165
Seekingalpha · 05/05 20:08
Cerus Q1 EPS $(0.07) Beats $(0.09) Estimate, Sales $43.00M Beat $38.98M Estimate
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 30 percent increase over losses of $(0.10) per share from the same
Benzinga · 05/05 20:05
More
No Data
Learn about the latest financial forecast of CERS. Analyze the recent business situations of Cerus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CERS stock price target is 9.40 with a high estimate of 11.50 and a low estimate of 7.50.
High11.50
Average9.40
Low7.50
Current 5.43
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 258
Institutional Holdings: 163.15M
% Owned: 92.23%
Shares Outstanding: 176.90M
TypeInstitutionsShares
Increased
67
5.57M
New
25
1.99M
Decreased
48
4.68M
Sold Out
24
1.81M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.86%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Swisher
Chief Executive Officer/President/Director
William Greenman
Chief Financial Officer/Vice President - Finance
Kevin Green
Chief Operating Officer
Vivek Jayaraman
Senior Vice President
Carol Moore
Chief Scientific Officer
Laurence Corash
General Counsel
Chrystal Menard
Other
Richard Benjamin
Independent Director
Eric Bjerkholt
Independent Director
Ann Lucena
Independent Director
Timothy Moore
Independent Director
Jami Nachtsheim
Independent Director
Gail Schulze
Independent Director
Frank Witney
No Data
No Data
About CERS
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.